Pancreas/Kidney Graft Improves Survival for Type 1 Patients Clinical Endocrinology News Digital Network After that time, patients receiving a single kidney began to receive basiliximab and the dual-transplant patients got thymoglobulin. The overall 15-year survival rate was 50% in the simultaneous-graft group, 30% in the living donor kidney group, and 12 ... |
